CEO at BIOAGE.
Kristen leads BIOAGE in its mission to develop a broad pipeline of therapies that target aging in order to increase healthspan and address chronic diseases. Kristen draws from a deep background in aging research and systems biology to develop BIOAGE’s data-driven approach to identify and target the molecular pathways that drive aging. Kristen received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research. She has over 10 years of experience developing novel bioinformatics approaches for data-driven investigation into the mechanisms of aging and age-related disease, with 18 published papers spanning computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity.
Visit website: https://bioagelabs.com/people/kristen.html
See also: BIOAGE - developing a broad pipeline of therapies to extend human healthspan and lifespan
Kristen Fortney is also referenced in the following:
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
BBC Click meets biohackers and companies who believe it will be possible to live on to well beyond 100
Kristen Fortney News
Bioage licenses new drugs to treat ageing and age-related diseases
Lifespan.io (LEAF) - 28-Apr-2021
Raised $90M in series C funding - off to a great start initiating three clinical trialsRead more...
BioAge's anti-ageing drug to treat Covid-19 enters phase 2 trial
Longevity Technology - 22-Mar-2021
Reverses immune ageing and can prevent death from coronavirus infection in the elderlyRead more...
Bioage's lead therapies moved closer to the clinic
Longevity Technology - 03-Dec-2020
Lead therapies of BioAge to treat age related diseases enter phase 2 trialsRead more...